Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | RXRB | P28702 | 4/20 | 0.42 |
| ▸ | RXRG | P48443 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355856 | 0.84 | CES2 (0.47) | CES2ALDH1A1LMNA | |
| SCHEMBL5764207 | 0.79 | NOTUM (0.46) | CES2ALDH1A1LMNAMAPTGPR35 | |
| SCHEMBL14372751 | 0.78 | GPR35 (0.46) | CES2ALDH1A1LMNAMAPTGPR35 | |
| Hydrochloric Acid SCHEMBL4499764 | 0.76 | ALDH1A1 (0.43) | CES2ALDH1A1MAPTNOTUM | |
| SCHEMBL25460762 | 0.73 | NOTUM (0.37) | RXRARXRBRXRGNOTUMACP1 | |
| SCHEMBL10898859 | 0.73 | MEN1 (0.42) | CES2LMNA | |
| SCHEMBL504013 | 0.72 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPT | |
| SCHEMBL531511 | 0.72 | CES2 (0.52) | CES2ALDH1A1RXRARXRBRXRG | |
| SCHEMBL4028192 | 0.72 | APP (0.53) | CES2ALDH1A1RXRARXRBRXRG | |
| SCHEMBL30221940 | 0.72 | CES2 (0.47) | CES2ALDH1A1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | CES2 811/4885ALDH1A1 1452/4885RXRA 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.